Last reviewed · How we verify
Neoadjuvant ipilimumab + nivolumab
Neoadjuvant ipilimumab + nivolumab is a Immune checkpoint inhibitor combination Small molecule drug developed by The Netherlands Cancer Institute. It is currently in Phase 3 development for Neoadjuvant treatment of resectable melanoma, Neoadjuvant treatment of resectable non-small cell lung cancer. Also known as: Yervoy + Opdivo.
This combination blocks two immune checkpoints (PD-1 and CTLA-4) to enhance anti-tumor immune responses before surgical resection.
This combination blocks two immune checkpoints (PD-1 and CTLA-4) to enhance anti-tumor immune responses before surgical resection. Used for Neoadjuvant treatment of resectable melanoma, Neoadjuvant treatment of resectable non-small cell lung cancer.
At a glance
| Generic name | Neoadjuvant ipilimumab + nivolumab |
|---|---|
| Also known as | Yervoy + Opdivo |
| Sponsor | The Netherlands Cancer Institute |
| Drug class | Immune checkpoint inhibitor combination |
| Target | PD-1 and CTLA-4 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Ipilimumab is a CTLA-4 inhibitor that removes inhibitory signals on T cells, while nivolumab is a PD-1 inhibitor that prevents tumor cells from suppressing T cell activity. Together, they synergistically activate the immune system to attack cancer cells in the neoadjuvant setting (before surgery), aiming to improve pathologic complete response rates and surgical outcomes.
Approved indications
- Neoadjuvant treatment of resectable melanoma
- Neoadjuvant treatment of resectable non-small cell lung cancer
Common side effects
- Fatigue
- Diarrhea
- Rash
- Immune-related pneumonitis
- Immune-related hepatitis
- Immune-related colitis
Key clinical trials
- Testing Nivolumab and Ipilimumab With Short-Course Radiation in Locally Advanced Rectal Cancer (PHASE2)
- A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma (PHASE2, PHASE3)
- Neoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon Cancer (PHASE2)
- Nivolumab With and Without Ipilimumab and Radiation Therapy in Treating Patients With Recurrent or Resectable Undifferentiated Pleomorphic Sarcoma or Dedifferentiated Liposarcoma Before Surgery (PHASE2)
- Testing the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid Mesothelioma (PHASE2)
- Integrated Pharmacokinetics (PK)/Efficacy, Safety, and Immunogenicity Study to Demonstrate Similarity of JPB898, a Proposed Biosimilar to Nivolumab, to Opdivo® in Combination With Yervoy® (PHASE3)
- Neo IRENIE (NEOadjuvant Ipilimumab, RElatlimab, NIvolumab Evaluation) (PHASE2)
- A Study to Test the Safety of Immunotherapy With Nivolumab Alone or With Ipilimumab Before Surgery for Bladder Cancer Patients Who Are Not Suitable for Chemotherapy (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Neoadjuvant ipilimumab + nivolumab CI brief — competitive landscape report
- Neoadjuvant ipilimumab + nivolumab updates RSS · CI watch RSS
- The Netherlands Cancer Institute portfolio CI
Frequently asked questions about Neoadjuvant ipilimumab + nivolumab
What is Neoadjuvant ipilimumab + nivolumab?
How does Neoadjuvant ipilimumab + nivolumab work?
What is Neoadjuvant ipilimumab + nivolumab used for?
Who makes Neoadjuvant ipilimumab + nivolumab?
Is Neoadjuvant ipilimumab + nivolumab also known as anything else?
What drug class is Neoadjuvant ipilimumab + nivolumab in?
What development phase is Neoadjuvant ipilimumab + nivolumab in?
What are the side effects of Neoadjuvant ipilimumab + nivolumab?
What does Neoadjuvant ipilimumab + nivolumab target?
Related
- Drug class: All Immune checkpoint inhibitor combination drugs
- Target: All drugs targeting PD-1 and CTLA-4
- Manufacturer: The Netherlands Cancer Institute — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Neoadjuvant treatment of resectable melanoma
- Indication: Drugs for Neoadjuvant treatment of resectable non-small cell lung cancer
- Also known as: Yervoy + Opdivo
- Compare: Neoadjuvant ipilimumab + nivolumab vs similar drugs
- Pricing: Neoadjuvant ipilimumab + nivolumab cost, discount & access